Immunovant (IMVT) Expected to Post Quarterly Earnings on Monday

Immunovant (NASDAQ:IMVT) is expected to announce its Q2 2027 results before the market opens on Monday, November 9th. Analysts expect Immunovant to post earnings of ($0.7370) per share and revenue of $7.09 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q2 2027 earnings overview page for the latest details on the call scheduled for Monday, November 9, 2026 at 8:00 AM ET.

Immunovant (NASDAQ:IMVT) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.75) EPS for the quarter, missing the consensus estimate of ($0.63) by ($0.12). The company had revenue of $7.09 million for the quarter, compared to analyst estimates of $7.09 million. During the same quarter in the previous year, the company earned ($0.71) EPS. On average, analysts expect Immunovant to post ($2.96) EPS for the current fiscal year and ($3.01) EPS for the next fiscal year.

Immunovant Price Performance

IMVT stock opened at $29.17 on Monday. Immunovant has a 12 month low of $21.43 and a 12 month high of $45.42. The company’s 50 day simple moving average is $34.56 and its 200-day simple moving average is $32.04. The firm has a market capitalization of $6.03 billion, a PE ratio of -10.34 and a beta of 0.95.

Insider Activity

In other news, COO Melanie Gloria sold 2,241 shares of Immunovant stock in a transaction that occurred on Wednesday, October 7th. The stock was sold at an average price of $32.06, for a total value of $71,846.46. Following the completion of the transaction, the chief operating officer owned 217,060 shares in the company, valued at approximately $6,958,943.60. This trade represents a 1.02% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Tiago Girão sold 6,606 shares of the business’s stock in a transaction that occurred on Wednesday, October 28th. The shares were sold at an average price of $28.50, for a total value of $188,271.00. Following the completion of the sale, the chief financial officer owned 234,192 shares of the company’s stock, valued at $6,674,472. This trade represents a 2.74% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 24,430 shares of company stock valued at $787,852 over the last three months. Company insiders own 1.90% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have issued reports on the stock. UBS Group reaffirmed a “buy” rating on shares of Immunovant in a research note on Wednesday, September 23rd. JPMorgan Chase & Co. increased their target price on shares of Immunovant from $47.00 to $50.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 4th. Citigroup reissued a “positive” rating on shares of Immunovant in a research report on Thursday, September 24th. Weiss Ratings restated a “sell (d-)” rating on shares of Immunovant in a research note on Friday, October 2nd. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Immunovant in a report on Tuesday, August 25th. Eight equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Immunovant currently has a consensus rating of “Moderate Buy” and an average target price of $44.00.

About Immunovant

Immunovant, Inc (NASDAQ: IMVT) is a clinical-stage biopharmaceutical company developing medicines for autoimmune diseases. The company focuses on conditions in which disease-causing immunoglobulin G (IgG) antibodies contribute to tissue damage and other symptoms.

Immunovant’s lead product candidate is batoclimab, also known as IMVT-1401, a fully human monoclonal antibody designed to inhibit the neonatal Fc receptor (FcRn). By reducing the circulation of pathogenic IgG antibodies, batoclimab is being evaluated as a potential treatment for autoimmune disorders, including generalized myasthenia gravis, thyroid eye disease and chronic inflammatory demyelinating polyneuropathy.